Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict
Advertisement

Related Content

Sequella CEO Carol Nacy On Partnering With Pfizer To Solve Multidrug-resistant TB
China's Changing Reimbursement Landscape Reshapes Pharma Market
China's Largest Pharma Promoter CMS Outpaced Market With Unique Specialty Pharma Focus
Bayer Donates A Second-line Defense Against China's Swelling Multidrug-resistant Tuberculosis
Pfizer's Salomon Azoulay And Bing Yan On Prevenar, Partnering In China Post-Lipitor: An Interview With PharmAsia News (Part 1 of 2)
China's Price Cuts And Antibiotic Limits Weigh On Simcere, But Merck JV Opens Doors
China's Pilot DRG Reimbursement Systems Indicate Substantial Changes To Hospital Prescription Habits
China To Issue Strict Limits On Antibiotic Usage By July; Large Sales Cuts Expected
China To Issue Strict Limits On Antibiotic Usage By July; Large Sales Cuts Expected
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
Advertisement
UsernamePublicRestriction

Register

SC078729

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel